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Abstract 
Antineoplastic platinum agents are used in first-line treatment of ovarian cancer, but treatment 
failure frequently results from platinum drug resistance. Emerging observations suggest a role of 
reactive oxygen species (ROS) in the resistance of cancer drugs including platinum drugs. However, 
the molecular link between ROS and cellular survival pathway is poorly understood. Using 
quantitative high throughput combinational screen (qHTCS) and genomic sequencing, we show 
that in platinum resistant ovarian cancer elevated ROS levels sustain high level of IL-11 by 
stimulating FRA1-mediated IL-11 expression and increased IL-11 causes resistance to platinum 
drugs by constitutively activating JAK2-STAT5 via an autocrine mechanism. Inhibition of JAK2 by 
LY2784544 or IL-11 by anti-IL-11 antibody overcomes the platinum resistance in vitro or in vivo. 
Significantly, clinic studies also confirm the activated IL-11-JAK2 pathway in platinum-resistant 
ovarian cancer patients, which highly correlates with poor prognosis. These findings not only 
identify a novel ROS-IL-11-JAK2-mediated platinum resistance mechanism but also provide a new 
strategy for using LY2784544 or IL-11-mediated immunotherapy to treat platinum-resistant 
ovarian cancer.  
Keywords: JAK2/IL-11/platinum drug/cisplatin resistance/ovarian cancer  
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Introduction 
Ovarian cancer is the fifth leading cause of cancer-related death among women and the deadliest 
gynecological cancer in the United States 31. The current standard treatment for ovarian cancer 
consists of surgery followed by platinum drug based chemotherapy 15, 21. Platinum drugs act by 
entering the nucleus of the cell and forming covalent adducts with DNA, thus decreasing cell 
viability 7. In addition to nuclear DNA damage, cisplatin can induce reactive oxygen species (ROS) 
response that can significantly enhance the cytotoxic effect 5, 20.  Up to 80% of patients with 
ovarian cancers initially respond to cisplatin-based chemotherapy and achieve remission 1, 4. 
However, cancer relapse occurs in about 80% of patients, and the relapsed ovarian cancer patients 
are more resistant to platinum-based therapy 11. Studies in the past characterized a plethora of 
mechanisms for cisplatin resistance, including reduced intracellular cisplatin accumulation, 
increases in metabolic inactivation of cisplatin, repair of cisplatin-induced DNA damage, and 
inactivation of p53 10, 36. Emerging observations also indicated a role of ROS in cisplatin resistance 
34. However, the detailed molecular mechanism of how ROS contributes to platinum drug 
resistance by regulating cell survival pathway remains largely unknown.  
Janus kinase 2 (JAK2) is a member of the Janus kinase family, which contains JAK1, JAK2, 
JAK3 and tyrosine kinase 2 (TYK2). JAKs are recruited to cellular membrane and activated by 
cytokine-activated receptors 28. Activated JAKs phosphorylate and activate signal transducer and 
activator of transcription (STAT) factors, which then translocate to nucleus to regulate the 
expression of genes involving in cell proliferation and apoptosis 29. Interleukin-11 (IL-11) is a 
member of the GP130 family that includes IL-6, IL-27, IL-31, OSM and LIF 3. IL-11 binds to the 
transmembrane receptor IL-11 Rα, causing activation of JAK2 and hence the downstream STAT 
pathway 2, 9.  However, the role of IL-11 in the response of cancer cells to chemotherapy remains 
largely unknown.  
In this study, for the first time, we provided an unbiased high throughput analysis to study 
platinum drug resistance in ovarian cancer by combined use of quantitative high-throughput 
combinational screening (qHTCS) and genomic sequencing techniques. The advantage of this 
approach is that it not only identifies novel drug combinations to treat drug resistance cancers but 
also discovers novel drug resistant mechanisms that cannot be identified by each technique alone. 
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Indeed,  we identified LY2784544, a JAK2 inhibitor under phase II clinical trial for 
myeloproliferative neoplasms 19, to be an effective drug to efficiently resensitize platinum drug 
resistant ovarian cancer in vitro and in vivo. Detailed mechanistic analyses indicated that in 
platinum-resistant ovarian cancer cells ROS promotes FRA1-dependent expression of IL-11, 
resulting in constitutive activation of JAK2-STAT5 pathway and resistance to platinum drugs. Most 
importantly, this novel mechanism is supported by our clinic findings: JAK2 activation correlates 
with high levels of IL-11 in the most tested platinum resistant ovarian tumors and the activated IL-
11-JAK2 pathway is correlated with a low overall survival rate of ovarian cancer patients receiving 
platinum drug-based chemotherapy.  
 
Results 
Establishment of platinum resistant ovarian cancer cells 
The objective of this study is to conduct both qHTCS and genomic sequencing using platinum drug 
resistant ovarian cancer cells to discover new mechanisms of resistance as well as novel drug 
combinations that can overcome platinum drug resistance (Fig. 1A). To accomplish this objective, 
we first established cisplatin resistant ovarian cancer cells using procedures as described 
previously and in methods 13. Specifically, starting with two ovarian cancer cell lines (SKOV3 and 
IGROV1), we obtained sub-cell lines, called SKOV3 CR and IGROV1 CR, that were able to grow in 
the medium containing a high concentration of cisplatin (Fig. 1B). Subsequent cell viability analyses 
revealed that the IC50 of cisplatin for SKOV3 CR was increased by 5-fold and IC50 of cisplatin for 
IGROV1 CR by 3-fold (Fig. 1B). SKOV3 CR cells were also resistant to carboplatin (Supplementary 
Fig. 1A), which is also used to treat ovarian cancer patients clinically 25. Apoptosis analyses 
indicated that cisplatin induced more apoptosis in SKOV3 cells than in SKOV3 CR cells 
(Supplementary Fig. 1B and 1C). Significantly, in vivo studies indicated that SKOV3 CR tumor was 
more resistant to cisplatin than SKOV3 tumor through anti-apoptosis (Supplementary Fig. 1D).  
            We next measured the DNA crosslinking in both cells post cisplatin treatment using a 
modified comet assay and found that there was no difference in the extent of cisplatin-DNA 
crosslinking between SKOV3 and SKOV3 CR cells 23 (Supplementary Fig. 1 E). Thus, SKOV3 CR cells 
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remain susceptible to cisplatin-induced DNA damage and it is unlikely that there are defects in 
cisplatin uptake.  
Identification of LY2784544 that overcomes cisplatin resistance via a qHTCS  
We employed these cells in a qHTCS to identify novel drug combinations to re-sensitize the cells to 
cisplatin. To this end, we screened a total of 6,016 compounds from multiple compound libraries 
including NPC (NCGC Pharmaceutical Collection), MIPE (Mechanism Interrogation Plate) and 
LOPAC (The Library of Pharmacologically Active Compounds). Two rounds of qHTCS screen were 
performed (Supplementary Fig. 2A). From the first screen, we identified a total of 112 compounds 
that efficiently inhibited the proliferation of SKOV3 CR cells (Supplementary Fig. 2B). To further 
identify compounds that have synergy with cisplatin, these 112 compounds were screened at 11 
different concentrations in combination with vehicle, 1 μM cisplatin or 20 μM cisplatin (Fig. 1C and 
Supplementary Fig.2A). Through this second screen, thirteen compounds that improved the 
cytotoxicity of cisplatin in SKOV3 CR cells were identified (Supplementary Table S1). In the next 
screen, cisplatin was tested at 11 different concentrations from 0.046 to 47 µM in combinations 
with these thirteen compounds (Supplementary Fig.2A). Three compounds, LY2784544 (JAK2 
inhibitor), MLN4924 (NEDD8 inhibitor) and NSC319726 (p53 mutant reactivator), were found to 
have significant reciprocal synergy with cisplatin on SKOV3 CR cells (Fig. 1C).  
Among the three compounds, LY2784544 has better cisplatin IC50 shift ability than 
MLN4924 or NSC319726, which significantly increased the sensitivity of SKOV3 CR cells to cisplatin 
to a degree similar to SKOV3 cells (Supplementary Fig. 2C, left panel). Cisplatin sensitized SKOV3 
CR cells to LY2784544 reciprocally (Supplementary Fig. 2C, right panel). The synergistic effects of 
MLN4924 or NSC319726 on cisplatin resistant ovarian cancer cells have been reported 
independently by other groups 13, 38, validating the use of this qHTCS to identify compounds 
overcoming cisplatin resistance. In subsequent studies, we mainly focused on investigating the 
mechanism by which LY2784544 overcomes cisplatin resistance of ovarian cancer cells.  
JAK2 inhibition synergizes with platinum drugs in platinum resistant ovarian cancer cells 
We conducted multiple analyses to confirm the synergistic effects of LY2784544 with cisplatin in 
cisplatin resistant SKOV3 CR cells. First, we measured cell proliferation using sulforhodamine 
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B (SRB) assay( and calculated the synergy between LY2784544 and cisplatin using Combenefit 8, 
and found excellent synergy in SKOV3 CR cells compared to that in SKOV3 cells (Fig. 1D and 
Supplementary Fig. 3A). We also calculated the combination index (CI), which quantitatively 
measures the interaction between two drugs (synergism: CI < 1; additive effect: CI = 1; and 
antagonism CI > 1)6. Significantly, the combination of cisplatin and LY2784544 exhibited excellent 
synergy on SKOV3 CR cells (mean CI = 0.69) and additive effect on SKOV3 cells (mean CI = 0.93) 
(Supplementary Fig. 3B). Using similar analysis, the combination of cisplatin and LY2784544 also 
had an excellent synergy (mean CI = 0.71) on IGROV1 CR cells (Fig. 1E).   
Given that both SKOV3 CR and IGROV1 CR cells acquired resistance under a cell culture 
condition, we next examined the synergy of LY2784544 and cisplatin in a paired ovarian cancer 
cells, PEO1 and PEO4, derived directly from one patient before and after chemotherapy 17. PEO1 
cells are platinum sensitive and PEO4 cells are platinum resistant cells. We did find that the IC50 of 
cisplatin for PEO4 cells was increased by 3-fold compared to that for PEO1 cells (Fig. 1F). 
Importantly, the combination of cisplatin and LY2784544 exhibited excellent synergy (mean CI = 
0.34) in PEO4 cells (Fig. 1G). 
Using a clonogenic assay, we found that SKOV3 CR cells exhibited a higher survival rate 
compared to SKOV3 cells after a cisplatin treatment. Combinatorial treatment with cisplatin plus 
LY2784544 significantly reduced the survival of SKOV3 CR compared to cisplatin or LY2784544 
treatment alone (Supplementary Fig. 3C). We also examined the synergy of LY2784544 with 
carboplatin in SKOV3 CR cells. Consistently, the combination of carboplatin and LY2784544 also 
exhibited an excellent synergistic effect (mean CI = 0.75) on SKOV3 CR cells (Supplementary Fig. 
3D).  
To confirm the JAK2 inhibitor’s effect on synergy with cisplatin, we next tested other two 
JAK2 inhibitors, TG101348 and TG-46. Similarly, both showed a synergistic effect with cisplatin on 
SKOV3 CR cells (Supplementary Fig. 3E and S3F). Taken together, our data strongly demonstrate a 
general synergistic effect of JAK2 inhibitors with platinum drugs on platinum drug resistant ovarian 
cancer cells.  
LY2784544 overcomes cisplatin resistance of ovarian cancer cells by inhibiting JAK2-mediated 
pathways in vitro and in vivo   
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We next explored the molecular mechanism by which the JAK2 signaling pathway confers cisplatin 
resistance in ovarian cancer. We first examined the activation of the JAK2-mediated pathway in 
three pairs of cisplatin sensitive (SKOV3, IGROV1, PEO1) and resistant (SKOV3 CR, IGROV1 CR, 
PEO4) cell lines. Compared to the three sensitive cell lines, the JAK2 protein levels were not 
altered in paired resistant cell lines (Fig. 2A). Strikingly, phosphorylation of JAK2 at Y1007/1008 
significantly increased in all resistant cells compared to their sensitive counterparts. Consistent 
with the activation of JAK2, we found the phosphorylation of STAT5 (Y694), a downstream target 
of JAK2 19, 37, was increased in all three resistant cell lines (Fig. 2A). The downregulation of JAK2 by 
shRNA significantly sensitized the SKOV3 CR cells to cisplatin (Fig. 2B and C), confirming that the 
cisplatin resistance in SKOV3 CR is JAK2-dependent.   
We next examined the effects of LY2784544 on the JAK2-STAT5 signaling pathway in both 
SKOV3 and SKOV3 CR cells. Apparently, LY2784544 significantly reduced the phosphorylation of 
both JAK2 and STAT5 in both SKOV3 and SKOV3 CR cells (Fig. 2D). Treatment of SKOV3 CR cells 
with LY2784544 efficiently decreased the activation of JAK2 and STAT5 but did not cause apoptosis 
as evidenced by a lack of cleaved PARP (Fig. 2E). However, the combination of cisplatin and 
LY2784544 not only reduced the phosphorylation of JAK2 and STAT5 but also enhanced apoptosis 
(Fig. 2E and F and Supplementary Fig. 4A).  
To determine whether LY2784544 can sensitize SKOV3 CR cells to cisplatin in vivo, we 
subcutaneously implanted SKOV3 CR cells into nude mice to form tumors, followed by various 
treatments. Although SKOV3 CR tumors were resistant to cisplatin or LY2784544, the 
combinatorial treatment with cisplatin and LY2784544 significantly not only reduced tumor 
growth (Fig. 2G), but also improved survival of the mice with SKOV3 CR tumors (Fig. 2H). To 
evaluate the efficacy of this combinational treatment and whether this in vivo tumor suppression 
was mediated through inhibition of JAK2, we collected SKOV3 CR xenograft tumor samples four 
days after full dosage treatment. Immunohistochemistry (IHC) analyses indicated that LY2784544 
treatment efficiently reduced the phosphorylation of JAK2 and the treatment with LY2784544 plus 
cisplatin significantly induced apoptosis in the tumor as indicated by TUNEL staining (Fig. 2 I-K). To 
evaluate the toxicity of treatment of cisplatin plus LY2784544 in mice, we carefully monitored the 
weight of the mice throughout the treatments and found that there was no significant reduction in 
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body weight during the whole treatment period (Supplementary Fig. 4B). No obvious 
histopathological alterations and lesions were found in liver and kidney of the treated animals 
(Supplementary Fig. 4C).  
The LY2784544 was reported as a selective JAK2 inhibitor 19. To confirm the selectivity of 
LY2784544, we conducted an in vitro kinase profiling to exam the interaction of LY2784544 with 
more than 450 human kinases. The results showed that LY2784544 exhibited stronger binding to 
JAK2 than JAK1 and TYK2 (Supplementary Fig. 4D), indicating the high selectivity of LY2784544 
towards JAK2. 
Identification of IL-11 as a key factor that regulates JAK2 activity in vitro and in vivo  
We next investigated how JAK2 is activated in cisplatin resistant ovarian cancer cells. Given that 
JAK2 could be constitutively activated by mutations including the V617F mutation 12, 16, 18, 22, 30, we 
first sequenced and compared the JAK2 gene in SKOV3 and SKOV3 CR cells (Supplementary Fig. 
5A). However, we did not find any mutations in the JAK2 gene in SKOV3 CR cells. 
Since cytokine-activated receptors can regulate the activation of JAK2 3, 24, 26, 35, we 
hypothesized that secreted factors in the medium of SKOV3 CR cells might cause, in an autocrine 
fashion, activation of JAK2, resulting in resistance to cisplatin. To test this possibility, we collected 
conditioned medium from SKOV3 CR cells and then used the medium to culture SKOV3 cells. 
Strikingly, SKOV3 cells cultured in the conditioned medium from SKOV3 CR displayed an increased 
resistance to cisplatin compared to cells cultured in the conditioned medium from SKOV3 (Fig. 3A), 
indicating that secreted factors from SKOV3 CR cells caused the cisplatin resistance of SKOV3 cells. 
Strikingly, SKOV3 cells cultured in the conditioned medium from SKOV3 CR cells activated JAK2 and 
STAT5 (Fig. 3B). 
To identify the cytokine factors in the conditioned medium from SKOV3 CR cells that active 
JAK2, we screened the cytokine levels in the conditioned medium of SKOV3, SKOV3 CR, PEO1, and 
PEO4 cells using a cytokine array. The result indicated significantly elevated levels of four cytokines 
(Eotaxin-2, Eotaxin-3, IL-11, and uPAR) in the medium of both SKOV3 CR and PEO4 cells compared 
with their parental cells (Fig. 3C and D). Furthermore, we also examined and compared gene 
expression profiles between SKOV3 and SKOV3 CR cells. There was a total of 1085 up-regulated 
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genes and 1686 down-regulated genes in SKOV3 CR compared to SKOV3 cells (Fig. 3 E). Comparing 
the genes in the cytokine pathways, we found that a total of 74 genes are either up- or down-
regulated (more than 2-fold change) in SKOV3 CR cells (Fig. 3F). We then compared these four 
cytokine genes with 30 up-regulated cytokine genes identified by genomic sequencing as well as 
155 genes involving in KEGG JAK/STAT signaling pathway (Pathway: map04630), and found that IL-
11 is the only up-regulated cytokine that is most likely to cause activation of JAK pathway in 
platinum drug resistant ovarian cancer cells (Fig. 3G). We therefore analyzed and compared IL-11 
mRNA levels by qPCR in sensitive and resistant cells and found that IL-11 mRNA levels increased 
significantly in all three resistant cell lines (Fig. 3H). Consistently, the amounts of secreted IL-11 
proteins in the medium of all three resistant cells were significantly higher than that in the 
medium of their sensitive counterparts (Fig. 3I). To rule out the possibility that JAK2-STAT5 
activation in the resistant cells might be due to the overexpression of IL-11 receptors, we next 
examined the expression of subunits of IL-11 receptor, including IL-11Rα, IL-6Rα, EPOR and G-CSFR, 
in SKOV3 and SKOV3 CR cells, and found that the levels of each protein did not increase in SKOV3 
CR compared to SKOV3 cells (Supplementary Fig. 5B). 
Given that both IL-11 mRNA and IL-11 protein are increased in the resistant cells, we 
hypothesized that IL-11 might also be up-regulated in cisplatin resistant ovarian tumors in vivo. To 
test this hypothesis, we examined the levels of IL-11 protein in SKOV3 and SKOV3 CR tumors by 
IHC and found that IL-11, as well as levels of phosphorylation of JAK2, were significantly increased 
in SKOV3 CR xenograft tumor cells (Supplementary Fig. 5C and S5D). Taken together, our results 
indicate that IL-11 levels are up-regulated in cisplatin resistant cancer cells in vitro and in vivo.  
Autocrine activation of IL-11 promotes cisplatin resistance by regulating JAK2-STAT5 activation 
in ovarian cancer cells 
The above findings suggested that IL-11 might be a critical factor contributing to cisplatin 
resistance by stimulating JAK2 activity in ovarian cancer cells. Therefore, we first tested whether 
IL-11 can stimulate the activation of JAK2 in SKOV3 cells.  Indeed, recombinant IL-11 treatment 
increased the phosphorylation of JAK2 and STAT5 (Fig. 4A). To support the notion that IL-11 
contributes to cisplatin resistance in ovarian cancer cells, we found that treatment of SKOV3 with 
recombinant IL-11 induced resistance to cisplatin (Fig. 4B). When IL-11 neutralization antibody was 
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added to the culture medium of  SKOV3 CR and IGROV1 CR, we observed reduced phosphorylation 
of JAK2 and STAT5 (Fig. 4C), and increased the sensitivity of the cells to cisplatin  (Fig. 4D, upper 
panel, SKOV3 CR; lower panel, IGROV1 CR). Thus, secreted IL-11 acts as an autocrine factor to 
stimulate the activation of the JAK2-STAT5 pathway, thereby inducing cisplatin resistance in these 
cells.   
To further test the relationship between IL-11 and cisplatin resistance in ovarian cancer 
cells, we depleted IL-11 by shRNA in SKOV3 CR cells and found that downregulation of IL-11 not 
only decreased the IL-11 secretion (Fig. 4E) but also reduced the activation of JAK2 and STAT5 (Fig. 
4F). More significantly, depletion of IL-11 re-sensitized SKOV3 CR cells to cisplatin (Fig. 4G). 
Addition of recombinant IL-11 to the medium restored the cisplatin resistance of SKOV3 CR cells 
with downregulated IL-11 by shRNA (Fig. 4H), indicating that reduced resistance by IL-11 depletion 
is not due to the shRNA off-target effect. To further confirm that IL-11-induced cisplatin resistance 
is JAK2-dependent, we downregulated JAK2 by siRNA in SKOV3 cells with recombinant IL-11 for 
four hours and then cisplatin treatment for five days (Fig. 4I). Although the addition of 
recombinant IL-11 could induce resistance to cisplatin in cells containing JAK2, IL-11 no longer 
induced cisplatin resistance in the cells with downregulated JAK2 (Fig. 4I). These findings indicate 
that JAK2 signaling is a major mechanism involved in IL-11-induced cisplatin resistance in SKOV3 
cells. 
Cisplatin induces IL-11-mediated autocrine activation of JAK2-STAT5 in vitro and in vivo 
We next explored the molecular mechanism of how ovarian cancer cells acquire resistance to 
cisplatin during cisplatin treatment, which can explain how ovarian cancer patients develop 
resistance to platinum drugs after receiving platinum-based therapy.  
Given that the elevated IL-11 stimulates JAK2 activation to induce cisplatin resistance, it is 
highly possible that cisplatin may result in increased expression and secretion of IL-11 as a 
compensatory surviving mechanism. To avoid cell death, we treated cells with cisplatin less than 
50% of IC50. Indeed, the small dosage of cisplatin treatment increased secretion of IL-11 in SKOV3 
cells, and furthermore, IL-11 secretion appeared to be dependent on cisplatin doses and 
treatment time (Fig. 5A).  IL-11 mRNA levels were also increased in cells following cisplatin 
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treatment (Fig. 5B), indicating that elevated secretion of IL-11 is due to up-regulated expression of 
IL-11 gene. As expected, JAK2 and STAT5 were activated after cisplatin treatment (Fig. 5C).  
  To further test whether ovarian cancer cells have a similar response to cisplatin in vivo, we 
treated SKOV3 xenograft tumor with various doses of cisplatin for 2 weeks (Fig. 5D). Four days 
after the last treatment, blood and tumor samples were collected for analyses of IL-11 levels. 
Significantly, cisplatin treatment dramatically increased human IL-11 levels in the serum of mice 
(Fig. 5E).  IHC analysis indicated a significant increase of IL-11 as well as pJAK2 levels in SKOV3 
tumors (Fig. 5F). Interestingly, the levels of both IL-11 and pJAK2 in the tumors were dependent on 
cisplatin doses: the higher the cisplatin dose the higher the levels of IL-11 and pJAK2 (Fig. 5G). Thus, 
cisplatin treatment induces the activation of the IL-11-JAK2 pathway in tumor cells in vivo as well. 
These results provide in vivo and in vitro evidence that may explain how ovarian cancer patients 
develop IL-11-JAK2-mediated platinum drug resistance.  
ROS induces autocrine activation of IL-11 by promoting expression of FOSL1 (FRA1)  
The next question is how IL-11 is activated in platinum drug resistant ovarian cancer cells. Since 
DNA damage induces ROS generation 14, 33, we next investigated whether ROS is involved in up-
regulation of IL-11. To this end, we first compared ROS level between SKOV3 and SKOV3 CR cells. 
Strikingly, the basal ROS level in SKOV3 CR cells was significantly higher than that in SKOV3 cells 
(Fig. 6A). To investigate if ROS in SKOV3 CR cells regulate IL-11 expression, we treated SKOV3 CR 
cells with a ROS inhibitor YCG063 and found that inhibition of ROS significantly reduced IL-11 
secretion as well as JAK2 and STAT5 phosphorylation (Fig. 6B-D and Supplementary Fig. 6A), 
indicating that ROS is critical for the secretion of IL-11 in cisplatin resistant cells. Next, we treated 
SKOV3 cells with cisplatin, YCG063 or in combination. Cisplatin treatment alone remarkably 
activated ROS production while YCG063 suppressed it in SKOV3 cells (Fig. 6E and Supplementary 
Fig. 6B). Furthermore, inhibition of ROS in SKOV3 cells suppressed the cisplatin-induced IL-11 
secretion (Fig. 6F), phosphorylation of JAK2 and STAT5 (Fig. 6G).  
              Having found that the ROS regulates IL-11 secretion, we then decided to identify critical 
ROS responsive genes that regulate IL-11 expression. To achieve this goal, we first conducted 
pathway analyses using PathwayNet and identified a total of 20 transcription factors that likely 
regulate IL-11 27(Fig. 6H). By comparing these candidate genes with the genes identified from RNA-
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Seq analyses, we found that the FOSL1 is the only gene that is significantly up-regulated by more 
than 2-fold in SKOV3 CR cells (Fig. 6H). Further analyses indicated that  the levels of FOSL1-
encoded protein, FRA1, and phosphorylated (Ser265) FRA1 were increased in SKOV3 CR cells 
compared to SKOV3 cells (Fig. 6I). Depletion of  FRA1 by FOSL1 siRNA significantly reduced IL-11 
secretion in SKOV3 CR cells (Fig. 6J and K), indicating that FRA1 is critical for IL-11 expression. We 
next tested whether ROS is required for activation or expression of FRA1 by treating SKOV3 CR 
cells with YGC063. Significantly, inhibition of ROS reduced the expression of FRA1 as well as its 
phosphorylation (Fig. 6L), indicating that the ROS signaling is required for the activation of FRA1.  
Clinical evidence of activated IL-11-JAK2 pathway in platinum drug resistant ovarian cancer 
patients   
To investigate and confirm the role of the IL-11-JAK2 pathway in platinum drug resistance 
of ovarian cancer patients, we first compared the IL-11 mRNA levels from patient samples of a 
total of 23 platinum sensitive patients and 16 resistant patients (Supplementary Table S2). We 
found that IL-11 levels in the platinum drug-resistant group are higher than that in sensitive group 
(Fig. 7A). Significantly, the group of patients with higher mRNA levels of IL-11 exhibited worse 
prognosis in terms of PFS and OS than the group with low mRNA IL11 level (Supplementary Fig. 7A). 
We also examined and compared the serum IL-11 levels from a total of 21 platinum sensitive 
patients and 16 resistant patients (Supplementary Table S3). We found that the platinum drug-
resistant group had a mean level of 120.2 pg/ml of serum IL-11, which is significantly higher than 
the platinum drug sensitive group (22.8 pg/ml of IL-11) (Fig. 7B). Also, the group of patients with 
higher serum levels of IL-11 (≥ 40 pg/ml) exhibited worse prognosis in terms of PFS and OS (Fig. 7C) 
than the group with low serum IL-11 level (< 40 pg/ml), indicating an inverse correlation between 
the serum levels of IL-11 and the survival rate of ovarian patients following platinum drug-based 
therapy. Out of these 37 patients, we identified one patient with both sensitive and resistant 
samples. The resistant tumors exhibited higher levels of IL-11 and p-JAK2 expression (Fig. 7D and 
Supplementary  Table S4). 
We also evaluated the correlation of the IL-11-JAK2 pathway in the samples from the same 
patient before platinum drug treatment and after tumor recurrence. We identified a total of seven 
patients who have received platinum drug based chemotherapy and had a recurrence 11-41 
13 
months post treatment (Supplementary Table S4). IHC staining indicated that IL-11 levels were 
increased in four of seven (57.1%) patients (Fig. 7E and Supplementary Fig. 7B). Strikingly, there 
was a significant correlation between IL-11 and pJAK2 levels in all tested primary and recurrent 
patient tumor samples (Fig. 7F).  
To further investigate the role of JAK2 activation in the regulation of platinum drug 
resistance in ovarian cancer, we next examined the correlation of the JAK2 activity with ovarian 
patient survival rate using large scaled ovarian cancer data bases. Since JAK2 phosphorylation but 
not proteins levels are up-regulated in platinum resistant cells, we therefore investigated the 
correlation of the JAK2 pathway with cisplatin resistance by analyzing and comparing the JAK2-
regulated functional pathways and gene expression profiles obtained from genomic sequencing. 
Specifically, we first analyzed the genes that are functionally linked with JAK2 by using PathwayNet 
and identified a total of 500 genes linked to JAK2 activity. Analyzing gene expression from RNA-Seq 
data, we identified a total of 1085 genes that are up-regulated at least 2-fold in SKOV3 CR 
compared to SKOV3 cells (Fig. 3E). Comparing these two sets of genes, we found a total of 22 
overlapped genes (Fig. 7G), which we named as JAK2 signature genes. Given that JAK2 activity is 
up-regulated in cisplatin resistant cells, we hypothesized that the levels of these JAK2 signature 
genes should inversely correlate to survival rate. We analyzed and compared JAK2 signature genes 
from 1816 patients found in 15 datasets using a Kaplan-Meier plotter 32. Indeed, patients with 
platinum drug treatment history exhibited a worse 5-year PFS and OS when JAK2 signature genes 
expression levels in their tumors were higher (Fig. 7H). Thus, a higher activity of the JAK2 pathway 
is highly correlated with worse ovarian cancer patient survival following platinum drug-based 
therapy. 
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In this study, we have demonstrated that qHTCS is an unbiased and quick method to study 
platinum drug resistance in ovarian cancer. The advantage of using such an approach is that it not 
only quickly identifies novel drug combinations in an unbiased manner but also the most likely 
drug target proteins and signal transduction pathways, especially those with post-transcriptional 
modification such as this JAK activation-mediated pathway. Specifically, we have successfully 
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identified that the elevated ROS production is responsible for activation of the IL-11-mediated 
autocrine mechanism that activates JAK-2-STAT5 signal transduction pathway to endow the 
ovarian cancer cells with cisplatin resistance (Supplementary Fig. 7C, left panel). Furthermore, 
targeting JAK2 or IL-11 can re-sensitize platinum drug resistant ovarian cancer cells to the platinum 
drug (Supplementary Fig.7C, right panel). Importantly, this novel molecular mechanism of 
platinum resistance has been confirmed by clinical studies. Thus, tumors with elevated IL-11 
production and JAK2 activity in patients are more likely to exhibit cisplatin resistance and patients 
with such tumors have a poor prognosis following platinum-based therapy.   
LY2784544 is currently investigated in clinical Phase 2 trial for its potential to treat 
myeloproliferative neoplasms (NCT01594723). Our studies indicate that LY2784544 can efficiently 
sensitize platinum resistant ovarian cancer cells to cisplatin both in vitro and in animals due to its 
ability to inhibit JAK2, thereby blocking the IL-11 autocrine mechanism for platinum resistance. 
Therefore, the use of specific JAK2 inhibitors, such as LY2784544, is likely to lead to a promising, 
more efficient combinatorial chemotherapy with platinum drugs as the first-line treatment for 
ovarian cancers or to treat relapsed ovarian cancer patients after platinum-based chemotherapy. 
Nevertheless, future clinical trials are needed to evaluate the safety and efficacy of the 
combination of platinum drugs and LY2784544 or other JAK2 inhibitors for ovarian cancer 
treatment. 
The discovery of an IL-11 autocrine mechanism that activates JAK2 and signals transduction 
to induce platinum drug resistance in ovarian cancer cells is exciting because it explains why 
ovarian cancer patients with high serum and tumor levels of IL-11 exhibit poor prognosis 
compared to those with low serum and tumor IL-11 levels. It is striking that elevated ROS levels 
are required to sustain high levels of IL-11 via regulating the expression of FRA1 (Fig. 6L). The ROS 
signaling can cause elevated expression of survival factors such as BCL-2 and MCL1 and decrease 
levels of cell death factors 34. However, the detailed molecular mechanism of how ROS regulates 
these factors is unknown. Thus, for the first time our studies provide a novel mechanism by which 
ROS promotes cell survival through stimulating FRA1-mediated expression of IL-11 in ovarian 
cancer cells to promote, in an autocrine fashion, their resistance to platinum drugs    
Our clinical findings indicate that platinum drug treatment of patients does increase the 
serum levels of IL-11, which is consistent with our findings in animals. Thus, this study suggests a 
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new strategy to increase the efficacy of platinum-based therapy for ovarian cancer and may be for 
other cancer types – that is, to develop and use agents, such as humanized monoclonal antibodies 
against IL-11 and/or IL-11Rα, to sensitize platinum resistant ovarian cancer to platinum drugs 
again.  However, since cisplatin treatment stimulates the expression of IL-11 in tumor cells, there 
is more reason to consider the combined use of a platinum drug with an agent that targets IL-11 or 
IL-11Rα to prevent cancer cells from acquiring resistance to the platinum drugs during treatment. 
Given that we can monitor the serum IL-11 level in patients, measurement of serum IL-11 level 
also provides us with a useful biomarker to evaluate the potential resistance of patients to 
platinum drugs. However, this hypothesis needs to be carefully evaluated using a large cohort of 
ovarian cancer patients in future studies.  
 
Materials and Methods 
Cell lines and resistance cell line establishment The human ovarian cancer cell line SKOV3 was 
obtained from the American Type Culture Collection (ATCC). PEO1, PEO4, and PEA1 were from 
Sigma-Aldrich. IGROV1 was a kind gift from Wei Zheng. SKOV3 cells were cultured in McCoy's 5A 
Medium supplemented with 10% fetal bovine serum (FBS). A2780, IGROV1, PEO1, PEO4, and PEA1 
cells were cultured in RPMI-1640 supplemented with 10% FBS. The cisplatin resistant cell line 
SKOV3 CR and IGROV1 CR were generated by treated with cisplatin for six cycles (4 hr cisplatin 
treatment, followed by release to cisplatin free medium for three weeks). Only early-passage (< 10 
passages) resistant cells were used for the study. All cells were cultured at 37 °C in a humidified 
incubator containing 5% CO2. 
Quantitative high-throughput combinational screening (qHTCS) Compound screening 
experiments were performed as previously described 32.  
Cell viability assay Cell viability was determined by a sulforhodamine B (SRB) assay as described 
previously 37.  
Animal experiments The detailed procesure of animal experiments is provided in Supplementary 
data.  
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Cytokine array Cytokine arrays on cell culture medium were performed using the Human Cytokine 
Antibody Array Kit (Abcam, 120 Targets) according to the manufacture’s protocol. Single intensity 
was analyzed using ImageJ (NIH) software. The results were then normalized using internal 
controls, and the relative protein levels were determined across four biological replicates. 
ELISA The cell-free culture medium, mouse serum, and patient serum were were analyzed for IL-
11 levels  using a human IL-11 ELISA kit (R&D Systems) according to the manufacturer's 
instructions. The absorbance was read at 450 nm using a microplate reader (BioTek).  The data 
were normalized to the cell number.  
Reactive oxygen species (ROS) detection ROS was detected with a live cell-permeable, 
fluorophore CellROX Orange reagent (Thermo Fisher Scientific) according to the manufacturer’s 
instructions. After treatment, cells were incubated with CellROX Orange reagent and Hoechst 
(Thermo Fisher Scientific)  at 37 °C for 30 min, followed by washing twice with prewarmed PBS. 
Cells were imaged using a Nikon Eclipse 80i microscope. ROS intensity was analyzed using ImageJ 
(NIH) software. 
Patients The detailed information on human patients is provided in Supplementary data.  
Statistical analysis Each value reported represents the mean ± standard error of the mean (SEM) 
or mean ± standard deviation (SD) as noted in the figure legends. A Student’s t-test was used to 
analyze differences in tumor volumes between two groups. For comparisons between multiple 
groups, a one-way ANOVA or two-way analysis was used with a Bonferroni post-test.  For Kaplan 
Meier survival analysis, a Log-rank (Mantel-Cox) test was used to compare each of the arms. All 
statistical tests were two-sided. Differences were considered statistically significant at a P value of 
less than 0.05. All statistical analyses were performed with GraphPad Prism, software version 7.00. 
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Figure legends  
Figure 1. Identification of LY2784544 that re-sensitize platinum-resistant ovarian cancer cells to 
platinum drugs by qHTCS 
(A) Schematics illustration of the combination of qHTCS and genomic sequencing for the 
identification of potent compounds to overcome platinum resistant as well as for the identification 
of novel cisplatin resistant mechanisms. Alphabetical letters indicate potential targeting pathways.  
(B) Viability of SKOV3 and SKOV3 CR cells (left), IGROV1 and IGROV1 CR (right) treated with 
increasing concentrations of cisplatin for 5 days. The IC50 was indicated. 
(C) Heatmap: enrichment of SKOV3 CR for a strong response to specific drug categories (rows) 
combine with cisplatin. Drug-category-response scores are based on IC50 (µM). The three 
compounds with reciprocal synergy with cisplatin are indicated.  
(D) Synergy matrix (bottom) and surface plots (top) showing the synergy between cisplatin and 
LY2784544 in SKOV3 and SKOV3 CR cells (n = 3).  
(E) The synergistic effects of LY2784544 and cisplatin on IGROV1 CR cells. CI values are presented 
below the bars.  
(F) Viability of PEO1 and PEO4 cells treated with increasing concentrations of cisplatin for 5 days. 
The IC50 was indicated. 
(G) The synergistic effects of LY2784544 and cisplatin on PEO4 cells. The CI values are presented 
below the bars.  
In all panels of this figure, data are represented as mean ± SD from three independent experiments 
performed in triplicate.   
 
Figure 2. LY2784544 targets JAK2 signaling in platinum resistant ovarian cancer cell in vitro and in 
vivo 
(A) Phosphorylation of JAK2 and STAT5 in parental and platinum resistant ovarian cancer cells. 
(B) JAK2 knockdown by shRNA decreases phosphorylation of JAK2 and STAT5 in puromycin-selected 
SKOV3 CR cells. 
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(C) Viability of SKOV3 CR cells treated with increasing concentrations of cisplatin for 5 days after 
JAK2 knockdown. Data are represented as mean ± SD from three independent experiments 
performed in triplicate.  ***p < 0.001 by two-way ANOVA. 
(D) LY2784544 down-regulates JAK2-STAT5 signaling in SKOV3 CR cells. Cells were treated with the 
indicated concentrations of LY2784544 for 48 hr. 
(E) Immunoblotting for the indicated proteins in SKOV3 CR cells treated with vehicle, 3 μM 
LY2784544, 5 μM cisplatin, or the combination (Combo) for 48 hr. 
(F) Apoptosis percentage of SKOV3 CR cells treated with vehicle, 3 μM LY2784544, 5 μM cisplatin, 
or the combination (Combo) for 48 hr and analyzed for Annexin V and Propidium Iodide staining by 
flow cytometry. Data are represented as mean ± SD from three independent experiments 
performed in triplicate.  **p < 0.01, ***p < 0.001, n.s. means not significant by one-way ANOVA. 
(G) Growth curves of SKOV3 CR xenograft tumors treated with vehicle, LY2784544 (15 mg/kg/day 
intraperitoneally), cisplatin (8 mg/kg/week intraperitoneally), or LY2784544 plus cisplatin (Combo) 
for 2 weeks. Data are represented as means ± SEM, n = 6 mice/group. ***p < 0.001 by two-way 
ANOVA. A photograph of the representative tumor from mice in each treatment arm is shown. 
Ruler scale is in cm. 
(H) Kaplan-Meier survival curves of SKOV3 CR tumor-bearing mice treated with cisplatin and/or 
LY2784544 as in (G). The endpoint was scored when a tumor reached 1.5 cm or when a mouse 
showed any sign of distress. (n = 6, *p < 0.05, **p < 0.01 by log-rank (Mantel-Cox) test). 
(I) Representative hematoxylin and eosin (H&E), IHC and TUNEL staining of tumor samples from 
mice treated with cisplatin and/or LY2784544, tumors were collected 4 days after the last 
treatment. Scale bar, 100um for H&E and pJAK2 IHC, 50 μm for TUNEL. 
(J) Quantification of IHC staining for pJAK2 in tumors treated as in (I). n = 5 mice/group.  Data are 
represented as means ± SEM. *p < 0.05, **p < 0.01, **p < 0.001, n.s. means not significant by one-
way ANOVA.  
(K) Quantification of apoptotic cells in tumors treated as in (I). Data are represented as mean ± SD. 
n = 5 mice/group. ***p < 0.001, n.s. means not significant by one-way ANOVA. 
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Figure. 3. IL-11 regulates JAK2 activity and cisplatin resistance in ovarian cancer cells 
(A) Viability of SKOV3 cells treated with increasing concentrations of cisplatin for 5 days after 
pretreatment for 2 days with the indicated amount of conditioned medium from SKOV3 or SKOV3 
CR cells. Data are represented as mean ± SD from three independent experiments performed in 
triplicate. CM, conditioned medium. *p < 0.05, **p < 0.01, ***p < 0.001 by Student’s t-test. 
(B) Phosphorylation of JAK2 and STAT5 in SKOV3 cells after pretreatment for 2 days with the 
indicated amount of conditioned medium from SKOV3 or SKOV3 CR cells. CM, conditioned 
medium. 
(C and D) Representative image (C) and quantification (D) of cytokine arrays of the expression 
levels of the indicated cytokines detected in the culture medium of paired cisplatin-sensitive 
(SKOV3, PEO1) and resistant (SKOV3 CR, PEO4) ovarian cancer cells. Data are represented as mean 
± SD. Numbers above the symbols show the fold change of cytokines in paired cisplatin-sensitive 
and resistant ovarian cancer cells. 
(E) Volcano plot showing up-regulated and down-regulated genes in SKOV3 CR compared with 
SKOV3. A change is considered significantly if the p-value is < 0.05 and the change is > 2-fold. 
Genes with very significant p-values are shown in the figure with p-value=1×10-5. The bright area in 
the plot indicates the high density of genes. 
(F) Hierarchical clustering of selected cytokine genes reveals a significant 2-fold change in SKOV3 
CR compared with SKOV3. Colors in the heatmap represent the gene expression levels after z-score 
normalization across different samples.  
(G) Venn diagram shows the overlap of genes in the KEGG JAK/STAT signaling pathway (Pathway: 
map04630), genes identified by genomic sequencing of SKOV3/SKOV3 CR cells and genes 
identified by the cytokine array. 
(H and I) Bar graphs showing the levels of mRNA (h) and secreted IL-11 (i) and in ovarian cancer 
parental cells (SKOV3, IGROV1, PEO1) and cisplatin resistant cells (SKOV3 CR, IGROV1 CR, PEO4). 
Levels of IL-11 mRNA and IL-11 protein were measured by RT-qPCR and ELISA respectively and are 
shown as means ± SD from three independent experiments performed in triplicate. **p < 0.01 by 
Student’s t-test. 
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Figure 4. IL-11-mediated autocrine mechanism promotes cisplatin resistance via regulating JAK2-
STAT5 activation in ovarian cancer cells  
(A) Immunoblotting of phosphorylated JAK2 and STAT5 in SKOV3 cells treated with 10 ng/mL of IL-
11 for 4 hr. 
(B) Viability of SKOV3 cells incubated with 10 ng/mL of IL-11 for 4hr and then treated with 
increasing concentrations of cisplatin for 5 days. Data are represented as mean ± SD from three 
independent experiments performed in triplicate. **p < 0.01, ***p < 0.001 by Student’s t-test. 
(C) Immunoblotting of phosphorylated JAK2 and STAT5 in SKOV3 CR and IGROV1 CR cells treated 
with control mouse IgG or neutralizing anti-IL-11 antibody for 4 hr. 
(D) Viability of SKOV3 CR (top) and IGROV1 CR (bottom) cells incubated with a control mouse IgG 
or an IL-11 neutralizing antibody for 4 hr and then treated with increasing concentrations of 
cisplatin for 5 days. Data are represented as mean ± SD from three independent experiments 
performed in triplicate. **p < 0.01, ***p < 0.001 by Student’s t-test. 
(E) The levels of IL-11 secretion in SKOV3 CR cells transfected with IL11 shRNA and selected with 
puromycin. ***p < 0.001 by one-way ANOVA. 
(F) Immunoblotting of phosphorylated JAK2 and STAT5 in SKOV3 CR cells transfected with IL11 
shRNA and selected with puromycin. 
(G) Viability of SKOV3 CR cells treated with increasing concentrations of cisplatin for 5 days after IL-
11 knockdown with IL11 shRNA. Data are represented as mean ± SD from three independent 
experiments performed in triplicate.  ***p < 0.001 by two-way ANOVA. 
(H) Recombinant IL-11 reversed the effect of IL11 shRNA on the sensitivity of SKOV3 CR cells to 
cisplatin. SKOV3 CR shIL-11 cells were incubated with IL-11 (17 pg/ml for SKOV3 CR shIL11-1; 47 
pg/ml for SKOV3 CR shIL11-2; calculated from 5e) for 4 hr and then treated with 1 μM of cisplatin 
for 5 days. Data are represented as mean ± SD from three independent experiments performed in 
triplicate.  **p < 0.01, ***p < 0.001 by one-way ANOVA. 
(I) Knockdown JAK2 by siRNA block IL-11 mediated resistance of SKOV3 cells to cisplatin. SKOV3 
cells were transfected with JAK2 siRNA for 24hr and then incubated with recombinant IL-11 for 4 
hr, followed by increasing concentrations of cisplatin treatment for 5 days. ***p < 0.001 by two-
way ANOVA.         
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Figure 5. Cisplatin treatment induces IL-11 secretion and JAK2-STAT5 activation in vitro and in vivo 
(A) IL-11 levels measured by ELISA in the medium of SKOV3 cells treated with cisplatin of various 
dosages for 4 days (left) and 1μM for various times (right) as indicated. Data are represented as 
mean ± SD from three independent experiments performed in triplicate.  **p < 0.01, ***p < 0.001 
by one-way ANOVA.  
(B) IL11 mRNA were measured by qPCR in SKOV3 cells treated with cisplatin of various dosages for 
4 days (left) and 1 μM for various times (right)  as indicated. Data are represented as mean ± SD 
from three independent experiments performed in triplicate. **p < 0.01, ***p < 0.001 by one-way 
ANOVA.  
(C) Levels of phosphorylated JAK2 and STAT5 in SKOV3 cells treated with cisplatin of various 
dosages for 4 days (left) and 1μM for various times (right)  as indicated.  
(D) A schematic presentation of the experimental set-up. 
(E) Serum IL-11 levels measured by ELISA in mice bearing SKOV3 xenograft tumors and treated with 
vehicle or cisplatin (2 - 6 mg/kg/twice a week intraperitoneally for 2 weeks) as in (D). Data are 
represented as mean ± SD. n = 3 mice/group. ***p < 0.001 by one-way ANOVA. 
(F) Representative H&E and IHC images of SKOV3 xenograft tumors treated as in (D).  
(G) Quantification of IHC staining for pJAK2 and IL-11 in tumors as in (F). Data are represented as 
means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, n.s. means not significant by one-way ANOVA. 
 
Figure 6. ROS induces IL-11 expression by promoting expression of FOSL1 (FRA1) 
(A) Representative images (left) and quantification (right) of reactive oxygen species (ROS) 
production in SKOV3 and SKOV3 CR cells. Data are represented as means ± SD from three 
independent experiments. **p < 0.01 by Student’s t-test. Scale bar, 100 μm.  
(B) Quantification of reactive oxygen species (ROS) production in SKOV3 CR cells after treated with 
the ROS inhibitor YCG063 20 μM for 24 hr. Data are represented as means ± SD from three 
independent experiments. ***p < 0.001 by Student’s t-test. 
(C) IL-11 levels measured by ELISA in the medium of SKOV3 CR cells treated with YCG063 20 μM for 
24 hr. Data are represented as mean ± SD from three independent experiments performed in 
triplicate. ***p < 0.001 by Student’s t-test.  
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(D) Immunoblotting of phosphorylated JAK2 and STAT5 in SKOV3 CR cells treated with YCG063 (20 
µM) for 24 hr. 
(E) Quantification of reactive oxygen species (ROS) production in SKOV3 cells after treated with the 
ROS inhibitor YCG063 (20 µM), cisplatin (1 µM), or both for 24 hr. Data are represented as means ± 
SD from three independent experiments. **p < 0.01, ***p < 0.001, n.s. means not significant by 
one-way ANOVA. 
(F) IL-11 levels measured by ELISA in SKOV3 cells treated with YCG063 (20 µM), cisplatin (1µM) or 
both for 24 hr. Data are represented as mean ± SD from three independent experiments performed 
in triplicate. ***p < 0.001 by one-way ANOVA.  
(G) Immunoblotting of phosphorylated JAK2 and STAT5 in SKOV3 CR cells treated with YCG063 (20 
µM), cisplatin (1µM) or both for 24 hr. 
(H) Heatmap of transcription factors that can potentially regulate IL11 in SKOV3 and SKOV3 CR. 
Colors in the heat-map represent the gene expression levels after z-score normalization across 
different samples. Fold change bar on the right shows that FOSL1 is the most significant up-
regulated gene. 
(I) Total and phosphorylated levels of FRA1 in SKOV3 and SKOV3 CR cells. 
(J) Depletion of FOSL1 by siRNA decreases the phosphorylated and total FRA1 protein levels in 
SKOV3 CR cells 
(K) IL-11 levels measured by ELISA in the medium of SKOV3 CR cells transfected with FOSL1 siRNA 
for 48 hr. Data are represented as mean ± SD from three independent experiments performed in 
triplicate. ***p < 0.001 by Student’s t-test. 
(L) Immunoblotting of phosphorylated and total FRA1 protein in SKOV3 CR cells treated with 
YCG063 20 µM for 24 hr. 
 
 
Figure 7. Clinical evidence of activated IL-11-JAK2 pathway in platinum drug resistant ovarian 
cancer patients   
(A) Comparison of the mRNA IL-11 levels measured by qPCR in platinum sensitive (n = 23) and 
resistant (n = 16) ovarian cancer patients. *p < 0.05 by unpaired student t-test. Sen, sensitive cases. 
Res, resistant cases.  
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(B) Comparison of the serum IL-11 levels measured by ELISA in platinum sensitive (n = 21) and 
resistant (n = 16) ovarian cancer patients. **p < 0.01 by unpaired student t-test. Sen, sensitive 
cases. Res, resistant cases.  
(C) Kaplan–Meier survival curves showing 5-year PFS rate (left panel) and OS rate (right panel) of 37 
ovarian cancer patients as shown in (d), who were stratified by serum IL-11 levels (40 pg/ml); log-
rank (Mantel-Cox), P values and HRs are shown. 
(D) Representative IHC image (left panel) and quantification (right panel) of the cisplatin sensitive 
and resistant tumor samples from the same patient (P1). 
(E) IHC quantification of IL-11 and p-JAK2 in platinum sensitive and recurrent tumor samples from 
seven patients (P2-P8). Data are represented as mean ± SD. 
(F) Scatter plots showing a correlation between IL-11 and pJAK2 levels in both primary and 
recurrent patient tumors (P2-P8). 
(G) Venn diagram indicating the overlap of genes in the JAK2 functional gene set and up-regulated 
genes set in SKOV3 CR compared with that in SKOV3 cells (left panel). The heatmap (right panel) 
shows 22 overlapped genes (JAK signature gene set). Colors in the heatmap represent the gene 
expression levels after z-score normalization across different samples. 
(H) Kaplan–Meier analyses of 5-year PFS rate (left panel) and OS rates (right panel) based on 
clinical and molecular data for ovarian cancer patients (n = 502 for PFS, n = 478 for OS). The 
patients were stratified by the expression levels in their tumors of the JAK2 signature genes. 
Medium survival, log-rank (Mantel-Cox) p values and HRs are shown. 
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Table S1. Compounds of secondary hits by qHTCS 
Sample Name Primary MOA 
 
Diff 
AUC 
Diff 
IC50 
  (μM) 
Vehicle 20 μM Cisplatin 
 IC50(μ
M) 
AUC 
IC50(μ
M) 
AUC 
Ingenol mebutate PKC Activator 
 
112.60 
7352.9
4 
null 0.00 0.01 112.60 
LY2784544 Jak2 inhibitor  9.36 31.63 8.56 74.73 0.27 84.09 
GSK-2636771 PI3Kbeta inhibitor  47.17 19.95 27.06 39.73 1.36 86.91 
Delanzomib Proteasome Inhibitor  29.49 19.95 3.41 102.73 0.17 132.22 
Bortezomib Proteasome Inhibitor  10.16 5.01 0.34 138.79 0.07 148.95 
Marizomib Proteasome Inhibitor  7.80 2.51 0.14 165.67 0.05 173.47 
MLN-4924 
NEDD8-Activating Enzyme (NAE) 
Inhibitors 
 
131.54 1.58 1.71 6.19 1.08 137.73 
Digoxin Steroid  65.87 0.79 0.11 99.52 0.14 165.40 
Ouabain octahydrate null  54.35 0.79 0.11 100.19 0.14 154.54 
Triptolide 
Inhibition of RNA polymerase II 
mediated transcription 
 
75.31 0.63 0.01 1.53 0.02 76.84 
G-Strophanthin Na+/K+-ATPase Inhibitors  89.18 0.63 0.07 83.23 0.11 172.42 
NSC319726 Mutant p53 Activator  63.60 0.50 0.04 33.55 0.09 97.15 
Thapsigargin PKC Activator  92.02 0.40 0.01 24.37 0.03 116.39 
MOA, mechanism of action; Diff, difference; AUC, area under the curve.  
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Table S2. Correlation between patient serum IL-11 level and clinical characteristics of HKU qPCR set 
Characteristics          Total 
         mRNA IL-11 Level  
OR 95% CI P-value 
Low High 
All Cases  39 20 (51.3%) 19 (48.7%)     
Age (years)        
    ≥50 15 6    (40.0%) 9   (60.0%)     
    <50 22 14  (63.6%) 8   (36.3%)  0.381 0.11-1.49  0.156 
Stage         
    I 10 6   (60.0%) 4   (40.0%)     
    II 5 2   (40.0%) 3   (60.0%)     
    III 17 7   (41.2%) 10 (58.8%)     
    IV 7 5   (71.4%) 2   (28.6%)     0.495 
Histological type        
   Serous 17 10 (58.8%) 7   (41.2%)     
   Nonserous 232 10 (45.5%) 12 (54.5%)  1.714 0.49-6.20  0.408 
Grade        
    1 7 4   (57.1%) 3   (42.9%)     
    2 10 5   (50.0%) 5   (50.0%)     
    3 22 11 (50.0%) 11 (50.0%)     0.943 
PFS, progressive free survival; OS, overall survival. 
P-value calculated by Chi-square test. 
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Table S3. Correlation between patient serum IL-11 level and clinical characteristics of HKU ELISA set 
Characteristics          Total 
          Serum IL-11 Level  
OR 95% CI P-value 
<40 pg/ml ≥40 pg/ml 
All Cases  37 20 (54.1%) 17 (45.9%)     
Age (years)        
    ≥50 22 14 (63.6%) 8   (36.4%)     
    <50 15 6   (40.0%) 9   (60.0%)  2.625 0.67-9.29  0.156 
Stage         
    I 7 5   (71.4%) 2   (28.6%)     
    II 2 2   (100%) 0   (0%)     
    III 21 10 (47.6%) 11 (52.4%)     
    IV 7 3   (42.9%) 4   (57.1%)     0.354 
Histological 
type 
       
   Serous 14 8   (57.1%) 6   (42.9%)     
   Nonserous 23 12 (52.2%) 11 (47.8%)  1.222 0.31-4.12 0.769 
Grade        
    1 4 3   (75%) 1   (25%)     
    2 12 8   (66.7%) 4   (33.3%)     
    3 21 9   (42.9%) 12 (57.1%)    0.282 
PFS, progressive free survival; OS, overall survival. 
P-value calculated by Chi-square test. 
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Table S4. Patient characteristics of HKU IHC set   
Patient 
Age 
(years) 
Stage  Histology Grade Chemotherapy 
PFS after chemo 
(months) 
1 54 IIIC Mucinous 2 Carboplatin + Taxol 11 
2 58 IC Clear cell 3 Carboplatin + Taxol 41 
3 50 IIC Endometrioid 3 Carboplatin + Taxol 34 
4 68 IIIC Serous N/A Carboplatin + Taxol 25 
5 56 IC Clear cell 1 
Carboplatin + Taxol+ 
Bevacizumab 
30 
6 78 IC Serous 3 Carboplatin 22 
7 55 IIIC Clear cell 3 Carboplatin + Taxol 47 
8 38 IIIC Serous 3 
Carboplatin + Taxol+ 
Bevacizumab 
18 
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Supplementary Methods 
Antibodies and reagents 
The antibodies for western blotting were obtained from the following companies:  Cell Signaling 
Technology (PARP, pJAK2 (Y1007/1008), JAK2, pSTAT5 (Y694), STAT5, pFRA1 (Ser265), FRA1, pChk1 
(Ser317) and Chk1); Santa Cruz Biotechnology (Caspase-9, IL-11Rα, IL-6Rα, EpoR, G-CSFR); Sigma-
Aldrich (GAPDH). The antibodies for immunohistochemistry were from Abcam (pJAK2 (Y1007/1008) 
and IL-11). The antibody for IL-11 neutralization was from R&D systems (IL-11). Cis-
Diamineplatinum(II) dichloride (cisplatin), carboplatin, and Solutol HS 15 were purchased from 
Sigma-Aldrich. LY2784544 and TG101348 were purchased from Selleckchem, TG46 was purchased 
from SynKinase. Pru, MLN4924 were purchased from Millipore. Recombinant human IL-11 was 
purchased from R&D systems. YCG 063 was purchased from Calbiochem.  
 
Compound libraries 
To identify compounds that can overcome cisplatin resistance, 6016-compounds from the three 
compound collections were screened. The library of pharmacologically active compounds (LOPAC®) 
of 1280 compounds (1) was purchased from Sigma. The NCGC Pharmaceutical Collection (NPC) of 
2816 compounds and mechanism interrogation plate (MIPE) library of 1920 compounds were 
previously described (2,3). Compounds from all libraries were obtained as powder and dissolved in 
dimethyl sulfoxide (DMSO). using Prism software (GraphPad). 
Quantitative high-throughput combinational screening (qHTCS) 
SKOV3 CR were plated at 1,500 cells/well in 5 µL assay medium (DMEM+10% FBS) in 1536-well 
polystyrene plates (Greiner Bio-One) and incubated for 16 hr. Cisplatin was freshly prepared in 0.9% 
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sodium chloride solution. One microliter of cisplatin in assay medium was transferred into each 
well of the assay plate using Multidrop Combi (Thermo Fisher Scientific) to reach a final 
concentration of 20 µM; 23 nL of the second drug in the 1536-well compound plate was 
transferred into the assay plate using NX-TR pin tool station (WAKO Scientific Solutions). After 72 
hr incubation, 4 µL/well ATP detection solution from an ATP content cell viability assay kit 
(Promega) was added into the assay plate using Multidrop Combi. Following another 30 mins 
incubation at room temperature, the luminescence signal was measured using a ViewLux plate 
reader (PerkinElmer). The primary screen data and curve fitting were analyzed using software 
developed at the NIH Chemical Genomics Center (NCGC) 39. In the qHTCS, the cytotoxic effect of a 
two-drug combination was compared to that of single drug. Briefly, the first compounds at 11 
concentrations were tested with IC20 and IC50 of a second compound or vehicle (control). A 
heatmap of the drug combinations was constructed where columns enumerate cisplatin/vehicle, 
rows enumerate the other drug, and heat map elements are IC50. The IC50 values were computed 
by fitting the concentration response titrations (using the normalized, corrected signal) to the hill 
equation from which the IC50 values were calculated as the concentration at which the fitted 
curve reaches 50% of maximum. Half maximal inhibitory concentration (IC50) values were 
calculated .  
Animal experiments 
Four to six weeks old female BALB/c athymic nude mice (CByJ.Cg-Foxn1nu/J) were purchased from 
the Jackson Laboratory. All studies involving mice were carried out in accordance with the National 
Institutes of Health regulation concerning the care and use of experimental animals and with the 
approval of the Institutional Animal Care and Use Committees (IACUC) of the George Washington 
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University. The experiments were approval by the Institutional Animal Care and Use Committees 
of the George Washington University Protocol A305. To establish the subcutaneous cisplatin 
sensitive and resistant xenografts. 4 × 106  SKOV3 or SKOV3 CR cells were suspended in 100 µl PBS 
and injected into the dorsal flank of each mouse. When the average tumor volume reached 100-
150 mm3, the mice were randomized into subsequent experiment groups. Cisplatin was given 
intraperitoneally at 8mg/kg weekly for two weeks, and LY2784544 was given intraperitoneally at 
15 mg/kg daily for 2 weeks. Tumors were measured twice per week. The relative tumor volumes 
were calculated using the formula: a×(b2) / 2, for which a and b represent the longest and shortest 
diameters, respectively. For survival studies, animals were sacrificed when tumors reached 1.5 cm3 
or when they showed any signs of distress such breathing disorders, weight loss, or immobility. 
For serum marker and tumor histology evaluation, blood and tumor samples were obtained from 
the animals 4 days after the final administration for subsequent evaluation. For single cisplatin 
treatment using SKOV3 tumors, cisplatin was given intraperitoneally at 2 mg/kg, 4 mg/kg and 6 
mg/kg twice a week for two weeks. Serum and tumor were collected 4 days after final 
administration of the drug. 
 
Flow cytometry  
 Apoptosis was analyzed by using FITC Annexin-V Apoptosis Detection reagents (BD Pharmingen) 
according to the manufacturer’s instructions. Cells were treated with the testing agents for 48hr 
and then treated with 0.25% trypsin. We then washed cells with cold PBS twice and re-suspended 
cells in binding buffer (1 x 106 cells /ml). Next 100μl of the cell suspension (1 x 105 cells) was 
incubated with 5 μl of Annexin-V FITC and 5 μl of propidium iodide (PI) for 15 min at room 
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temperature in the dark. The population of apoptosis cells were analyzed by flow cytometry (BD 
Biosciences). 
Modified comet assay 
Modified comet assay was performed as according to the instruction of the CometAssay® Kit 
(Trevigen). In brief, cells were incubated with or without cisplatin for 2 hours. DNA was randomly 
broken into fragments using irradiation at the dose of 20 Gy. Cells (10 μL in PBS) were mixed with 
100 μL of 1.2 % low melting point agarose and were plated on CometAssay Kit slides. After cells 
were lysed, DNA was separated from cells by electrophoresis at 20 voltages and 300 mA for 45 
minutes. The tail moment was visualized by staining with 100 μL of 10000-fold diluted SYBR Geen® 
I. The tail moments of at least 50 cells of each treatment were analyzed with OpenComet software. 
The degree of DNA interstrand crosslinking (ICLs) present in a drug-treated sample was 
determined by comparing the tail moments of the irradiated control according to the formula: 
percentage of DNA with ICLs = (1 – (TMcispt -TMuc/TMic- TMuc)) × 100 %. TMcispt means the tail 
moment of the cisplatin-treated irradiated sample, TMuc indicates the tail moment of untreated 
non-irradiated control, and TMic is a tail moment of untreated irradiated control. 
Clonogenic assay 
To determine the capacity of clonogenic survival, cells were plated in 60-mm dishes at a density of 
300 cells per dish and cultured overnight. Cells were then treated with the drugs at indicated 
concentrations. Cells were kept in the incubator for 14 days to allow colony formation. The 
medium was removed, and cells were fixed and stained with 0.5 % crystal violet. Colonies with >50 
cells were counted. 
KINOMEscan profiling of LY2784544 
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The KINOMEscan profiling of the LY2784544 was assessed in competition binding assays, using a 
panel of 468 recombinant kinases (DiscoveRx) as described (4). The binding interactions are 
reported as “% Ctrl”, where lower numbers indicate stronger interactions. Selectivity score or S-
score is a quantitative measure of compound selectivity. It is calculated by dividing the number of 
kinases that compounds bind to by the total number of distinct kinases tested, excluding mutant 
variants. 
JAK2 coding region sequencing  
The mRNAs in  SKOV3 and SKVO3 CR cells were extracted using RNA extraction kit (Qiagen) and 
were further converted into cDNA by reverse transcriptase (Invitrogen). The Jak2 coding region 
was amplified in five fragments using specific pairs of primers: fragment 1, 5’- AGG CAA CAG GAA 
CAA GAT GTG AAC-3’ and 5’- AAG GAC CAC TTC CAG GTT CTT TTA-3’, fragment 2, 5’-CAA AGA TCC 
AAG ACT ATC ATA TTT T-3’ and 5’- TTA TAT TGT CTG AGC GAA CAG TTT C-3’, fragment 3, 5’- GAA 
ACT GTT CGC TCA GAC AAT ATA A-3’ and 5’- CTT TGA GAA TCC AGA GCA CTT AGA G-3’, fragment 4, 
5’- TAA ACC TCT AAG TGC TCT GGA TTC T-3’ and 5’- TCT CCA ATT TTA ACT CTG TTC TCG T-3’, 
fragment 5, 5’- AGT ACA CAT CTC AGA TAT GCA AGG G-3’ and 5’- GGT CTC AGA ATG AAG GTC ATT 
TC-3’. All the PCR products were sent to Eurofin for DNA sequencing. The sequences of JAK2 
coding region in SKOV3 and SKVO3 CR cells were compared and aligned with each other and with 
JAK2 sequence obtained from NCBI database (Gene ID: 3717) using M-Coffee alignment(5).  The 
known JAK2 point mutations were also surveyed in SKOV3 and SKVO3 CR cells(6) . 
RNA-sequencing analysis  
SKOV3 and SKOV3 CR cells growing in log phase were harvested.  RNA isolation was completed 
using the Qiagen miRNeasy Mini Kit, and then RNA samples were converted into cDNA libraries 
using the Illumina TruSeq Stranded mRNA sample preparation kit (Illumina # RS-122-2103).  Read 
counts of each sample were normalized with DESeq and ran a negative binomial two sample test 
to find significant genes in higher transcript abundance in either the SKOV3 or SKOV3 CR. The 
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genes had a false discovery rate (FDR) of < 0.05.  A fold change larger than 2 or smaller than 0.5-
fold were considered as differentially expressed genes. RNA sequencing data have been deposited 
in Gene Expression Omnibus (GEO) under accession number GSE98559. 
siRNA interference and shRNA  
JAK2 siRNA was purchased from Santa Cruz Biotechnology, FOSL1 siRNA was purchased from 
Thermo Fisher Scientific. Control Gl2 (luciferase) siRNA was as described previously (7). Cells were 
transfected once with siRNA using Lipofectamine RNAiMAX (Thermo Fisher Scientific) according to 
the manufacturer’s instructions. Cells were treated with the indicated agents for analyses 24 or 48 
hr after siRNA transfection. JAK2 shRNA, IL11 shRNA, and scramble control shRNA were purchased 
from OriGene. The lentiviral particles expressing these shRNA were packaged and used to infect 
cancer cells according to the manufacturer’s instructions. Cells were selected in puromycin for two 
weeks before used for the subsequent experiment. 
Immunohistochemistry 
Paraffin tissue sections were deparaffinized in xylene and hydrated with ethanol solutions. 
Antigen-retrieval treatment was performed at 121°C for 5 minutes in 10 mM sodium citrate buffer 
(pH 6.0). Slides were treated with 3% hydrogen peroxide in methanol solution for 10 minutes to 
quench endogenous peroxidase activity. Nonspecific bindings were blocked by treating slides with 
10% normal goat serum for 30 minutes. Slides were incubated with the primary antibody 
overnight at 4°C. Second antibody incubation, and DAB staining was using SuperPicture™ Polymer 
Detection Kit (Thermo Fisher Scientific) according to the manufacturer’s instructions.  The slides 
were lightly counterstained with hematoxylin.  
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For quantification of mouse IHC staining, each tumor sample was assessed in at least five fields at 
200× or 400× magnification. Immunoreactivity was evaluated semiquantitatively by staining 
intensity and proportion. The proportion of staining was scored from 0 to 3 as follows: 3, >50% of 
cells positive; 2, 10% to 49% of cells positive; 1, <10% of cells positive. Staining intensity was 
scored from 0 to 3 (0, absent; 1, weak; 2, moderate; 3, intense). The final IHC score for each 
sample was determined by multiplying the intensity and the proportion of stained cells. The 
analysis was undertaken blindly without knowledge of treatment variables. 
For quantification of patient IHC staining, the following formula was applied to get the H score.  H 
score = ∑ (1 + i) pi, in this formula, “i” is the intensity score (0, No staining; 1, Weak 
cytoplasmic/nuclear; 2, Moderate cytoplasmic; 3, Weak nuclear and cytoplasmic; 4, Moderate 
nuclear; 5, Strong cytoplasmic; 6, Strong nuclear; 7, Moderate nuclear and cytoplasmic；8，
Strong nuclear and cytoplasmic) and “pi” is the percent of the cells with this intensity.  The 
quantification of  IHC staining was scored blindly by three independent observers. 
TUNEL assay 
The In Situ Cell Death Detection Kit (Roche) was used to detect apoptotic tumor cells in vivo. In 
brief, paraffin tissue sections were deparaffinized in xylene and rehydrated in decreasing 
concentrations of ethanol. Slides were incubated in 0.1 % Triton X-100 (Sigma-Aldrich) for 8 
minutes. After wash with distilled water, slides were incubated in 3% hydrogen peroxide in PBS 
(pH 7.4) for 5 min. After washing with PBS, the slides were incubated in terminal 
deoxyribonucleotide transferase (TdT) at 37°C for 60 min. After washing with PBS, slides were 
incubated with horseradish peroxidase (POD) at 37°C for 30 min. DAB Substrate (Thermo Fisher 
Scientific) was used to demonstrate peroxidase activity. Slides were counterstained with 
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hematoxylin before observation. At least 2000 cells were counted under a microscope at 400x 
magnification in randomly-selected fields to quantify apoptosis. 
RT-qPCR 
RNA was extracted by using the RNeasy Mini Kit according to the manufacturer’s protocol 
(QIAGEN). 0.5µg of total RNA was reverse transcribed using the iScript SuperMix reagent (Bio-Rad). 
Primers used for qPCR were as follows: IL11 (human) Forward: 5′-TCT CTC CTG GCG GAC ACG-3′; 
Reverse: 5′-AAT CCA GGT TGT GGT CCC C-3′. GAPDH (human) Forward: 5'-GGA GCC AAA AGG GTC 
ATC AT-3'; Reverse: 5'-GTG ATG GCA TGG ACT GTG GT-3'. qPCR and fluorescence detection was 
performed using iQ SYBR Green Supermix (Bio-Rad) on an iCycler iQ real-time PCR detection 
system (Bio-Rad). Relative RNA levels were calculated from Ct values. 
Patients 
Serum and cDNA samples were obtained from ovarian cancer patients at Queen Mary Hospital 
from 1990 to 2016 and stored at the Department of Obstetrics & Gynaecology, The University of 
Hong Kong. Cases with chemosensitive and matched recurrent or chemoresistant tumor tissues 
were kept as formalin-fixed paraffin-embedded (FFPE) samples in the Department of Pathology at 
University of Hong Kong. All studies using human tissues were approved by the local institutional 
ethics committee (institutional review board reference No: UW 05-143 T/806 and UW 11-298). 
Written informed consent was received from patients prior to their inclusion in the study. The 
histological types, disease stages, and cancer cell contents in each FFPE sections were examined by 
the experienced pathologists. Written informed consent was given by the participants, and the use 
of the clinical specimens was approved by the local institutional ethics committee (institutional 
review board reference No: UW 05-143 T/806 and UW 11-298). The treatment of patients with 
ovarian cancer included total abdominal hysterectomy, bilateralsalpinpoophorectomy (BSO), and 
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staging procedure for early disease, or debulking for advanced disease followed by adjuvant 
chemotherapy which consisted of either cisplatin or carboplatin alone, or in combination with 
paclitaxel. The overall survival rate was defined as the length of time from the diagnosis or 
surgery/chemotherapy to either disease progression, recurrence, death or the last follow-up date 
of the patients. According to our definition of platinum responses 39, platinum-sensitive was 
defined as patients who have a total responses to platinum-based therapy and no recurrence 
within 6 months, whereas platinum resistance means patients who had the recurrence occur 
within 6 months following the completion of platinum-based therapy. Patients with platinum 
refractory tumors that could not achieve a complete response after the platinum therapy were 
also as those with platinum-resistance. 
Survival analysis in ovarian cancer  
An open access online tool KM plotter (kmplot.com/analysis) was used to analyze the relationship 
between IL11 and JAK2 signature gene expression from surviving ovarian cancer patient. 1816 
patient in a 15 microarray dataset (TCGA n = 565, GSE 14764 n = 80, GSE 15622 n = 35, GSE 18520 
n = 63, GSE 19829 n = 28, GSE 23554 n = 28, GSE 26193 n = 107, GSE 26712 n = 195, GSE 27651 n = 
49, GSE 30161 n = 58, GSE 3419 n = 116, GSE 51373 n = 28, GSE 63885 n = 101, GSE 65986 n = 55, 
GSE 9891 n = 285) were included in the survival analysis. For IL11 survival analysis, probe set 
206924_at was used. Results were generated by the input “serous histology”, “suboptimal debulk”, 
and “contains platin chemotherapy” and by the  “auto select best cutoff” option. For JAK2 
signature gene set survival analysis, a multigene classifier was used with probes: 204531_s_at 
(BRCA1), 221918_at (CDK17), 214453_s_at (IFI44), 204439_at (IFI44L), 212918_at (RECQL), 
209200_at (MEF2C), 203741_s_at (ADCY7), 203789_s_at (SEMA3C), 212507_at (TMEM131), 
232057_at (SLC7A6OS), 209666_s_at (IKKA), 206584_at (LY96), 202100_at (RALB), 202450_s_at 
(PKND), 224842_at (SMG1), 228333_at (ZEB2), 203710_at (Insp3r1), 227031_at (SNX13), 
235352_at (MR1), 205092_x_at (ZNF909), 206115_at (EGR3) and 204082_at. (PBX3). Results were 
11 
generated by using the input “contains platin chemotherapy” and by the  “auto select best cutoff” 
options. 
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Supplementary Figure 1. Establishment of platinum resistant ovarian cancer cell lines and 
identification of compounds that overcome cisplatin resistance  
(A) Viability of SKOV3 and SKOV3 CR cells treated with increasing concentrations of carboplatin for 
5 days. Data are represented as mean ± SD. The IC50 values represent the mean of two 
independent experiments performed in triplicate. 
(B) Representative flow cytometry dot plots (left) and quantification (right) of SKOV3 and SKOV3 CR 
cells treated with cisplatin for 48 hr and analyzed for Annexin V and Propidium Iodide staining by 
flow cytometry. **P < 0.01 by Student’s t-test. 
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(C) The effect of cisplatin on the proteolytic activation of caspase-9 and cleavage of PARP in the 
parental SKOV3 and SKOV3 CR cells. 
(D) Representative images (left) and quantification (right) of TUNEL staining of SKOV3 and SKOV3 
CR tumor xenografts after 4 days of treatment with cisplatin (2mg/kg or 4mg/kg twice per week for 
two weeks); n = 4 mice/group.  Scale bar, 50 μm. **p < 0.01, ***p < 0.001 by Student’s t-test; 
arrows indicate apoptotic cells. 
(E) Representative images (left) and quantification (right) from the modified comet assay 
performed after SKOV3 and SKOV3 CR cells had been treated with cisplatin for 2 hr followed by an 
irradiation treatment at 20 Gy. DNA ICLs: DNA interstrand crosslinking. Scale bar, 100 μm. n.s. 
means not significant by Student’s t-test 
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Supplementary Figure 2. Identification of compounds that resensitizes platinum drug by qHTCS 
(A) Flow chart for qHTCS compound screening using platinum resistant ovarian cancer cells. The 
criteria for compound selection and the number of compounds included at each step are listed. 
(B) Principal active 112 compounds from primary qHTCS screening, their mechanism of action, and 
their chemical genomic association in the top enriched network in MetaCore. 
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(C) LY2784544 and its dose-dependent effects on cells in the presence of cisplatin measured by 
qHTCS . Data are represented as mean ± SEM. The mechanism of action of the compounds are list 
in the table. 
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Supplementary Figure 3. LY2784544 synergies with platinum drugs by JAK2 inhibitors 
(A) Matrix representation of viability assay in SKOV3 (left)) and SKOV3 CR (right) cells treated with 
indicated concentrations of cisplatin and LY2784544 (n=3). 
(B) Isobologram analysis of the effects of cisplatin and LY2784544 at multiple concentrations on 
SKOV3 and SKOV3 CR cells in (A). Results are the mean values of three independent experiments 
performed in triplicate. CI, combination index. 
(C) Colony formation by SKOV3 and SKOV3 CR cells 14 days after they have been treated with 0.5 
µM cisplatin and/or 0.1 µM LY2784544. Colonies were stained with crystal violet. Data are 
represented as mean ± SD from three independent experiments performed in triplicate. **p < 
0.01, ***p < 0.00, n.s. means not significant by one-way ANOVA,  
(D) The synergistic effects of LY2784544 and carboplatin on SKOV3 CR cells. The CI values are 
presented below the bars. Data are represented as mean ± SD from three independent 
experiments performed in triplicate.   
(E) The synergistic effects of the JAK2 inhibitor TG101348 and cisplatin on SKOV3 CR cells.  The CI 
values are presented below the bars. Data are represented as mean ± SD from three independent 
experiments performed in triplicate.  
(F) The synergistic effects of the JAK2 inhibitor TG46 and cisplatin on SKOV3 CR cells. The CI values 
are presented below the bars. Data are represented as mean ± SD from three independent 
experiments performed in triplicate.  
In all panels of this figure, CI < 1 indicates synergism, CI = 1 indicates additive effect, and CI > 1 
indicates antagonism.  
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Supplementary Figure 4. LY2784544 in vitro kinase assay and in vivo toxicity  
(A) Representative flow cytometry plots of Apoptosis of SKOV3 CR cells treated with vehicle, 3 μM 
LY2784544, 5 μM cisplatin, or the combination (Combo) for 48 hr.  
(B) Body weights of SKOV3 tumor-bearing mice during treatment as in Fig. 3g. Data are 
represented as means ± SEM, n = 6 mice/group.   
(C) Representative histopathology of liver and kidney collected from mice treated as in Fig. 3i. Scale 
bar, 100 μm. 
(D) Binding interactions of 43 hits reported as ≤1 % percent of control in KinomeScan assay. The 
lower numbers indicate stronger interactions by LY2784544. 
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Supplementary Figure 5. JAK2 gene analysis and receptor expression 
(A) Comparison of high frequent point mutations in SKVO3 and SKOV3 CR.  
(B) Immunoblotting of JAK2-related receptors in SKOV3 and SKOV3 CR cells. 
(C) Representative H&E and IHC images of SKOV3 and SKOV3 CR tumor xenografts. Scale bar, 100 
μm.  
(D) Quantification of IHC staining for pJAK2 and IL-11 in tumors as in (J). Data represented as 
means ± SEM. ***p < 0.001 by Student’s t-test. 
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 Supplementary Figure 6. Effects on cisplatin-induced IL-11 secretion by ATR inhibitor or ROS 
inhibitor   
(A) Representative images of reactive oxygen species (ROS) production in SKOV3 CR cells in the 
absence or presence of YCG063 (20 μM) for 24 hr. Scale bar, 100 μm.  
(B) Representative images of reactive oxygen species (ROS) production in SKOV3 cells after treated 
by vehicle, YCG063 (20 µM), cisplatin (1 µM) or both (Combo) for 24 hr. Scale bar, 100 μm.  
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Supplementary Figure 7. IL-11 and JAK2 pathway in platinum drug resistant ovarian cancer 
patients   
(A) Kaplan–Meier survival curves showing 5-year PFS rate (left panel) and OS rate (right panel) of 
39 ovarian cancer patients as show in Fig.8g, who were stratified by IL11 mRNA levels by median 
cutoff); log-rank (Mantel-Cox), P values and HRs are shown. 
(B) Representative IHC images of IL-11 and p-JAK2 in platnium sensitive and recurrent tumor 
samples from one patient (P2). 
(C) Schematics of IL-11-JAK2-mediated pathway in the regulation of platinum drug resistance in 
ovarain cancer.  Left: ROS-mediated activation of IL-11-JAK2 pathway leads to platinum drug 
resistance in ovarian cancer. Right: inhibition of JAK2 or IL-11 resensitizes platinum drug resistant 
ovarian cancer cells to platinum drugs. 
 
 
 
 
 
 
 
 
 
 
 
